Key result
The addition of biomarkers of multimorbidity and biological ageing to laboratory tests of coagulation slightly improved discrimination for clinically important bleeding (AUROC 0.701) but did not improve clinical utility.
Why the study?
To test whether adding biomarkers of multimorbidity and biological ageing improves the predictive accuracy of point-of-care viscoelastometry or laboratory coagulation tests for clinically important bleeding after cardiac surgery.
Does the addition of biomarkers of multimorbidity and biological ageing to standard coagulation tests improve the prediction of clinically important bleeding in patients undergoing cardiac surgery?
Observational (n=2,437)
No
Does the addition of biomarkers of multimorbidity and biological ageing to standard coagulation tests improve the prediction of clinically important bleeding in patients undergoing cardiac surgery?
Adding biomarkers of multimorbidity and biological aging to standard coagulation tests slightly improves discrimination but not clinical utility for predicting excessive bleeding after cardiac surgery.
Biomarkers add little predictive value beyond standard coagulation tests for post-cardiac surgery bleeding; leaves open need for refined phenotypes and prospective validation.
Purpose We tested the hypothesis that addition of biomarkers of multimorbidity and biological ageing would improve the predictive accuracy of point-of-care viscoelastometry or laboratory tests of coagulation for clinically important bleeding following cardiac surgery. Methods The analyses included 2437 participants in the Coagulation and Platelet laboratory Testing in Cardiac surgery (COPTIC study) with complete clinical, TEG®5000 Thromboelastography, ROTEM®, Multiplate® aggregometry, full blood count, laboratory reference tests of coagulopathy, and biomarkers of biological ageing and multimorbidity. Models with different biomarkers to predict the composite primary outcome, Clinically Important Bleeding, was developed using logistic regression and internally validated using 10-fold cross-validation. Discrimination, calibration, and clinical utility of the models were assessed comprehensively. Results For the primary outcome, the AUROC for the best predictive model using TEG/ROTEM with other biomarkers was 0.694 (0.612–0.775). The best predictive model included laboratory reference tests of coagulation, full blood count results, and biomarkers of multimorbidity and ageing, AUROC=0.701 (0.620–0.781), although clinical utility was not superior to using laboratory reference tests alone. Discrimination was higher for components of the primary outcome; large volume (≥4 units) red cell transfusion 0.754 (0.602–0.903), and large volume procoagulant transfusion 0.723 (0.590–0.857), but not for excess loss in drains/re-sternotomy 0.701 (0.613–0.788). Calibration was generally good among the models. Conclusion Diagnostic tests for bleeding following cardiac surgery demonstrate moderate discrimination, although this was influenced by the definition of bleeding. Small improvements in discrimination with inclusion of additional disease biomarkers, with similar calibration and clinical utility. Take-home message 1. Current diagnostic tests demonstrate moderate predictive accuracy for excessive bleeding following cardiac surgery. In this study, addition of biomarkers of multimorbidity and biological ageing improved discrimination but not clinical utility. 2. Existing clinical definitions of bleeding represent heterogeneous phenotypes, presenting a barrier to research investigating the disease processes. Important abbreviations used in this paper: CIB – Clinically Important Bleeding CCB – Clinical Concern about Bleeding AUROC – Area Under the Receiver Operating Characteristic Curve
No takes yet. Share an insight, caveat, or question.
Liao et al. (2024) conducted an observational in Excessive bleeding following cardiac surgery (n=2,437). Biomarkers of multimorbidity and biological ageing added to laboratory tests vs. Laboratory reference tests alone was evaluated on Clinically Important Bleeding (CIB) (AUROC 0.701, 95% CI 0.620-0.781). The addition of biomarkers of multimorbidity and biological ageing to laboratory tests of coagulation slightly improved discrimination for clinically important bleeding (AUROC 0.701) but did not improve clinical utility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: